Editorial Board Members
Rami Aqeilan, Jerusalem
Rami Aqeilan is a group leader at the Hebrew University of Jerusalem, faculty of Medicine. He received his PhD in 2003 for his research on utilizing pro-apoptotic proteins in cancer cell targeting using chimeric proteins in the laboratory of Haya Lorberoum-Galski. Rami then preformed his post-doctoral studies at Carlo Croce’s laboratory at the Kimmel Cancer Center in Philadelphia investigating the role of gene products of common fragile sites (CFSs) in cancer and homeostasis. In 2005 he assumed his first faculty position as a Research Assistant Professor in the Department of Molecular Virology, Immunology and Medical Genetics at the Comprehensive Cancer Center in Ohio State University (Columbus, Ohio). In 2008 he joined the faculty of Medicine at The Hebrew University of Jerusalem. Rami has been studying the early events contributing to tumor initiation, in particular the contribution of CFS gene products, like WWOX and FHIT, to the tumorigenesis process. Another topic that is of Dr. Aqeilan’s research interest is regulation of the Hippo pathway in tumorigenesis. His research has taken advantage of mouse models, tissue culture and human clinical samples of osteosarcoma, breast cancer and pancreatic cancer.
Marie-Liesse Asselin-Labat, Melbourne
Marie-Liesse Asselin-Labat received her PhD from the University Paris XI in 2004 before moving to Melbourne, Australia, where she completed her postdoctural training in the Breast Cancer Laboratory at the Walter and Eliza Hall Institute of Medical Research. She joined the Stem Cells and Cancer Division at the Walter and Eliza Hall Institute of Medical Research as a Group Leader in 2011. She is the recipient of the L'Oreal For Women in Science Fellowship, the Centenary Institute Lawrence Creative prize and the Eureka Prize for Outstanding Young researcher. Her current research interests include the study of cellular and molecular mechanisms underlying lung development, activation of adult lung stem cells during repair and in lung diseases. Her laboratory most specifically focuses on the study of epigenetic regulators of embryonic and adult lung progenitor cells. She also investigates the cellular origin of lung cancer to decipher early events driving lung carcinogenesis.
Nick Barlev, Saint Petersberg
Nick Barlev has obtained his joined PhD degree from Kazan State University, Russia and University of Aarhus, Denmark. He carried out his postdoctural training on molecular mechanisms of transcription regulation in the laboratory of Dr. Shelley L. Berger at the Wistar Institute, Philadelphia. He joined Tufts University, Boston in 2002 as an Assistant Professor to work on the role of lysine-specific post-translational covalent modifications in regulation of tumor supressor p53. In 2008 he moved to the University of Leicester, UK where his lab worked on various aspects of lysine methylation in p53, E2F1 and other critical transcriptional regulators. In 2015 Dr Barlev became the Head of Gene Expression Regulation Unit in the Institute of Cytology, Saint Petersberg, Russia. His team investigates the role of p53 as a gene expression regulator, lysine-specific methylation in tumor suppression/progression, DNA Damage response, and control of protein translation by proteasome-mediated degradation.
Quan Chen, Bejing
Quan Chen is a Professor at State Key Laboratory of Biomembrane and Membrane Biotechnology in the Institute of Zoology, Chinese Academy of Sciences. He holds an adjunct appointment in the College of Life Sciences, Nankai University. Dr. Chen obtained his PhD in Cell Biology in the area of mitochondrial biology in 1993 from the Chinese Academy of Sciences. He then went to the School of Biological Sciences at the University of Manchester for his postdoctoral training under the supervision of Dr. Caroline Dive and Alastair Watson in John Hickman's laboratory. During that time he started to work in the area of apoptosis and drug resistance in cancers with a focus on mitochondria and Bcl-2 family proteins. He continued to work on the radiation induced apoptosis when he moved to the Cleveland Clinic Foundation in Dr. Alex Almasan's Laboratory in 1997 before he moved back to China in 2000 to start his own independent research laboratory. His research here focuses on the molecular regulation of mitochondrial apoptosis, mitochondrial dynamics and mitochondrial quality control. In particular, he wishes to understand how apoptotic signals are sensed by Bcl-2 and its family proteins to regulate mitochondrial permeabilization and cytochrome c release for the activation of apoptosis. Research from Dr. Chen's group is supported by peer reviewed grants from the Nature Science Foundation of China, the Ministry of Sciences and Technology of China and the Chinese Academy of Sciences.
Isaac Harris, Boston
Isaac S. Harris is a Postdoctural Research Fellow in the Department of Cell Biology at Harvard Medical School (HMS) in Boston, USA. Isaac completed his PhD in 2013 under the supervision of Tak W. Mak at Princess Margaret Hospital in Toronto, Canada. During this time, he developed a core foundation in translational research, including an expertise in mouse models of cancer. Isaac focused his efforts on investigating cancer metabolism, specifically the role of antioxidants in tumorigenesis. His work demonstrated the importance of glutathione and thioredoxin antioxidant pathways in tumor initiation and progression. Following his PhD, Isaac moved to Boston to begin a fellowship in the lab of Joan Brugge at HMS. While maintaining a focus on antioxidants, he has expanded his research to investigate novel therapeutic strategies for cancer. Through the development of high-throughput assays, Isaac has been able to investigate the interconnectivity of antioxidants with functional profiling of different cellular states of cancer.
Richard Killick, London
Richard Killick is a molecular neurobiologist, principal investigator and lecturer at King's College London, UK. Dr. Killick received his D.Phil. from Sussex University in 1994 following his investigations of molecular components forming the avian and mammalian auditory systems. He continued his career as a postdoctoral investigator at Sussex examining the developmental neurobiology of genes and proteins involved in Alzheimer's disease, within the inner ear. In 1999 he moved to King's College London, joining the Neuroscience department to further his investigations into the underlying cause of Alzheimer's disease and other neurodegenerative/neurological disorders. During this time his attention focused on cellular signaling pathways that underpin the neuropathology of Alzheimer's disease, particularly the Wingless/Wnt, Notch and Insulin pathways. In 2010 he established his own group at KCL and his current focus is on the role of the Wnt-Planar Cell Polarity pathway in Alzheimer's disease neuropathology and the central role pf p53 in the activation of this pathway by b-amyloid. His group have recently moved to the new, purpose built Maurice Wohl Clinical Neuroscience Institute. There he collaborates closely with a range of other neuroscientists, clinicians and structural biologists and is also involved in biomarker discovery and drug discovery programmes.
Inna Lavrik, Magdeburg
Professor Inna N. Lavrik heads the Translational Inflammation Research laboratory at the Medical Faculty of the Otto von Guericke University in Magdeburg, Germany. She completed her PhD studies at the Lomonosov Moscow State University and the Max Planck Institute of Molecular Genetics in Berlin, Germany. In 2000, she became a Postdoctoral Fellow investigating death receptor signaling networks in the Division of Immunogenetics at the German Cancer Research Center headed by Prof. Peter H. Krammer. In 2008, she joined Bioquant Systems Biology Center in Heidelberg as a group leader focusing on bio-computational studies of apoptosis. In 2012, she was appointed Professor in the Medical Faculty of the Otto von Guericke University in Magdeburg, Germany. Her current research includes the molecular mechanisms governing the function of macromolecular complexes in death receptor networks, their posttranslational modifications, and the computational modeling of apoptosis pathways.
Clare Parish, Melbourne
Associate Professor Clare Parish heads the Stem Cells and Neural Development laboratory at the Florey Institute of Neuroscience & Mental Health, the University of Melbourne, Australia. She obtained her PhD in neuroanatomy from Monash University, Australia and subsequently trained in stem cell biology at the Karolinska Institute (Stockholm, Sweden). she has a broad research interest relating to disease modeling and reparing the injured brain. Her research places a strong emphasis on understanding neural development, with the idea that repairing the injured brain will require recapitulation of many of these early events. Consequently her expertise encompasses; neural development, directed differentiation of pluripotent stem cells, molecular mechanisms underlying neural development and axonal targeting (with a particular interest in Wnts and chemokines), and improving cell-based therapies for neural injuries. In more recent years her research has expanded to also examine the potential of 3D bioengineered scaffolding in brain repair.
Alessandro Rufini, Leicester
Alessandro Rufini got his degree at the University of Rome "La Sapienza", working in the laboratory of Prof. Antonio Fantoni. Then he did an internship at the laboratory of Molecular Oncogenesis under the supervision of Dr. Marco Crescenzi at the Institute Regina Elena in Rome, before being employed at the Department of Toxicology and Etoxicology at the "Instituto Superiore de Sanita" (ISS), Rome. From 2002 he worked as a PhD student in Professor Gerry Melino's laboratory at the University of Rome Tor Vergata. During this time his research focused on the p53-family of transcription factors and their involvement in development. He then joined Prof. Tak W. Mak's laboratory at Campbell Family Institute for Breast Cancer Research, at the Princess Margaret Hospital in Toronto in 2006 as post-doc and continued working on the p53-family. In 2009 he moved to join Professor Gerry Melino at the MRC Toxicology Unit in Leicester, UK, working as investigator scientist until he was appointed to his current position as lecturer in the Department of Cancer Studies at the University of Leicester in 2013. Currently, he leads a research group focused on early detection of disease and exploitation of metabolic pathways for prevention and therapy of colon cancer. He has authored numerous peer reviewed articles and is on the editorial board of Frontiers in Cancer Molecular Targets and Therapeutics and Cell Death Discovery, while acting as reviewer for several peer reviewed jorunals.
A Emre Sayan, Southampton
A. Emre Sayan is an Associate Professor of Cancer Biology and a Lecturer at the University of Southampton, UK. Dr. Sayan received his PhD in 2002 for his research on p53 family member, p73. He continued his career as he did 3 postdoctural studies in INSERM U370 (Paris, France), MRC Toxicology Unit (Leicester, UK) and University of Leicester (UK) working on different aspects of cancer such as apoptosis, cell cycle and epithelial-mesenchymal transition. During that time, he identified caspases cleaving p53 family member proteins (p53, p63 and p73), cell cycle is attenuated during epithelial-mesenchymal transition and metastatic cells become chemoresitant by interrupting phosphorylation events upstream of AMTATR and p53. In 2010 he established his lab in Southampton. His current work includes biomarker-drug discovery to identify and target metastatic carcinoma cells, breaking chemoresistance barrier by combination therapy and targeting tumour microenvironment. He has close collaborations with clinicians, uses in vitro-in vivo cancer models and performs in vivo imaging to supplement his research.
Kate Schroder, Brisbane
Kate Schroder heads the Inflammasome Laboratory, and is Deputy Director of the Centre for Inflammation Research and Disease, at the Institute for Molecular Bioscience, University of Queensland, Australia. Kate received her PhD in 2005 for her research investigating mechanisms of macrophage activation by interferons and Toll-like receptors, in the laboratory of David Hume. Her subsequent postdoctoral position with David Hume and Matthew Sweet investigated the transcriptional programs triggered by macrophage differentiation and Toll-like receptor ligation. A key focus of these studies was to define species differences in the TLR4-dependent responses of human versus mouse macrophages. She then joined Jurg Tshopp's group in Switzerland as a Research Fellow, and gained expertise in Nod-like receptor and inflammasome biology. In 2013, she established her new laboratory, which integrates molecular and cell biology approaches with in vivo studies to gain a holistic understanding of inflammasome function during infection, and inflammasome dysfunction in inflammatory disease. Current research directions include the molecular mechanisms governing inflammasome activity and caspase activation, the evolutionary biology of inflammasomes, and the cellular mediators of inflammasome-dependent inflammation.
Katja Simon, Oxfor
Katja Simon is a principal Investigator and associate professor at the Weatherall Institute of Molecular Medicine, Oxford University UK, studying cell fates in the hematopoietic system. She trained as an Immunologist under Avrion Mitchison and found that TH1 cytokines are found in excess in human automimmune diseases in her PhD. As a postdoc at the Centre d'Immunologie Marseille Luminy, she investigated transcription factors regulating thymic cell death. During her second postdoc in Oxford she pursued her interest in cell fate, studying cell death molecules (Trail and FasL) in thymic selection, inflammation and tumor immunity. She set up an independent line of enquiry investigating autophagy, another cell fate, in the hemato-immune system. Her group discovered that autophagy, the main conserved cellular bulk degradation pathway, maintains healthy stem cells and promotes differentiation of many types of hematopoitec cells.
Mahvash Tavassoli, London
Mahvash Tavassoli completed her PhD in Molecular and Cellular Biology in 1987 at the University of Sussex, Brighton, UK, under the supervision of Prof. Sydney Shall. After a short postdoctoral training in the laboratory of Prof. Robert Eisenman, Fred Hutchinson Cancer Research Centre, Seattle, USA, she returned to the UK to work as a postdoctoral research fellow at the Centre for Medical Research, University of Sussex. In 1990 she obtained a Research Fellowship from Cancer Research UK to establish her own group in the School of Biological Sciences, University of Sussex to study the regulation of EGFR and HER-2 in breast cancers. After completing a short EMBO Fellowship in the laboratory of Prof. Axel Ullrich at King's College London, School of Medicine and Dentistry where she is currently a Professor and head of the Department of Molecular Oncology. Her research interest since studying for a PhD has been the understanding of the molecular pathogenesis of cancer. The focus of her research over the past 10 years has been the study of cell cycle regulation and the apoptosis machinery with the aim of developing molecular strategies to improve the detection and treatment of cancers in general and for head and neck cancers in particular. This work has resulted in several important breakthroughs in the understanding of the molecular pathways involved in the development, progression and treatment of head and neck cancers. Research of her group has been supported by grants from peer reviewed external sources including MRC, CRUK and Breast Cancer Research Trust.